Supported by more than 35 years of practiced experience in radiology, physics, and academia, Farrokh A. Dilmanian, Ph.D., is a renowned figure in his profession whose expertise is unparalleled. Serving as a professor of research in the departments of radiology, oncology, and neurology in the School of Medicine at Stony Brook University since 2013, he first joined the university as an employee in 1987. Alongside his primary appointment, he has served the Brookhaven National Laboratory in the department of medicine since 1986. Prior to these endeavors, he was a scientist in the Brookhaven National Laboratory from 1992 to 2011 and a visiting scientist in the department of nuclear physics at the Weizmann Institute of Science in Rehovot, Israel, in 1986. He commenced his career as chief scientist in the nuclear medicine division of Elscint Ltd. in Haifa, Israel, in 1983, holding the position for three years.
Noted for his research in developing new methods of radiation therapy that cause segmented x-ray beams, Dr. Dilmanian has researched carbon ion minibeams including the experimental method of “interleaved carbon minibeams,” where carbon minibeam arrays from 90-degree angles are interleaved at the target to produce a solid radiation field while exposing non-targeted tissue to single minibeam arrays. Bearing this research in mind, he is planning to use this technology for use in animal studies to evaluate its tumor control efficacy. Alongside Dr. James Hanfield of Nanoprobes, Inc., Dr. Dilmanian has also directly contributed to experimental radiation therapy through his research on dose-enhancing agents, such as gold nanoparticles.
To remain abreast of developments in the industry, Dr. Dilmanian maintains affiliation with Voices Against Breast Cancer, the Institute of Electrical and Electronics Engineers, and the Radiation Research Society. As a testament to his success, Dr. Dilmanian received the Patent Award from the Long Island Technology Fall of Fame in 2008.
Contact Dr. Dilmanian:
